ClinicalTrials.gg
CompletedNCT05630274Updated Sep 18, 2025Results posted

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

A Phase 1 interventional study of Selpercatinib and Moxifloxacin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Apr 2019, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, non-smoking, male or female (of non only or undergone sterilization procedures at least 6 months prior to the Screening) with no abnormalities.
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) at Screening and have a minimum weight of at least 50 kg at Screening
  • Female of non childbearing potential: must have undergone sterilization procedures at least 6 months prior to the Screening
  • Males who are capable of fathering a child must agree to use from the time of the dose administration through 6 months after the last dose

Exclusion criteria

Exclusion Criteria:

  • Estimated \<90 milliliter per minute (mL/min) at Screening or Check in (Day -1; rechecks will be permitted up to two times to confirm participant eligibility for study participation).
  • Has serum potassium levels \<3.8 milliequivalents per liter (mEq/L) at Screening or Check in (Day -1; rechecks will be permitted up to two times to confirm participant eligibility for study participation).
  • Has serum calcium levels \< 8.5 milligrams/deciliter (mg/dL) at Screening or Check in (Day -1; rechecks will be permitted up to two times to confirm participant eligibility for study participation).
  • Has serum magnesium levels \<2.0 mEq/L at Screening or Check in (Day -1; rechecks will be permitted up to two times to confirm participant eligibility for study participation)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: ABCD

    Period 1: 320 milligram (mg) Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 2: 640 mg Selpercatinib (Treatment B) Period 3: 400 mg moxifloxacin (Treatment C) Period 4: Selpercatinib matching placebo (Treatment D) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.

    Drug: Selpercatinib

  • Experimental
    Treatment Sequence 2: BDAC

    Period 1: 640 mg Selpercatinib (Treatment B) Period 2: Selpercatinib matching placebo (Treatment D) Period 3: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 4: 400 mg moxifloxacin (Treatment C) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.

    Drug: Selpercatinib

  • Active comparator
    Treatment Sequence 3: CADB

    Period 1: 400 mg moxifloxacin (Treatment C) Period 2: Selpercatinib matching placebo (Treatment D) Period 3: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Period 4: 640 mg Selpercatinib (Treatment B) Participants received their assigned treatments in each of the above treatment period on Day 1 orally. Period Title: Treatment Period 1

    Drug: Moxifloxacin

  • Placebo comparator
    Treatment Sequence 4: DCBA

    Period 1: Selpercatinib matching placebo (Treatment D) Period 2: 400 mg moxifloxacin (Treatment C) Period 3: 640 mg Selpercatinib (Treatment B) Period 4: 320 mg Selpercatinib and Selpercatinib matching placebo (Treatment A) Participants received their assigned treatments in each of the above treatment period on Day 1 orally.

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3527723, LOXO-292

  • Administered orally

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C

    The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect

    Time frame: Pre-dose, -0.25, -0.5, -0.25, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, and 24 hours post-dose

  2. Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    PK: AUC0-t of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  3. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

    PK: AUC0-inf of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  4. PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

    PK: AUC%extrap of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  5. PK: Maximum Observed Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  6. PK: Time to Reach Cmax (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  7. PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib

    PK: Kel of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  8. PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib

    PK: t½ of Selpercatinib is reported.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

07

Results

Posted Sep 18, 2025

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBA
Started8888
Received at least one dose of study drug8888
Completed8888
Not completed0000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBA
Started8888
Received at least one dose of study drug8888
Completed8888
Not completed0000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBA
Started8888
Received at least one dose of study drug8888
Completed8888
Not completed0000
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBA
Started8888
Received at least one dose of study drug8888
Completed8888
Not completed0000

Outcome measures

PrimaryCardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C

The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect

Time frame:
Pre-dose, -0.25, -0.5, -0.25, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, and 24 hours post-dose
Reported as:
Least squares mean · milliseconds
Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C
milliseconds320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)400 mg Moxifloxacin (Treatment C)
Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C3.4 (0.40 to 6.34)4.4 (1.37 to 7.40)6.4 (3.38 to 9.43)
PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

PK: AUC0-t of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · nanogram*hour per millilitre (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
nanogram*hour per millilitre (ng*h/mL)320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib33730 ± 42.342670 ± 65.8
PrimaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

PK: AUC0-inf of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
ng*hr/mL320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib33830 ± 42.342830 ± 65.7
PrimaryPK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

PK: AUC%extrap of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Mean · percentage of AUC0-inf extrapolated
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
percentage of AUC0-inf extrapolated320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib0.2986 ± 0.214640.3734 ± 0.53500
PrimaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
nanogram per milliliter (ng/mL)320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib2024 ± 74.62356 ± 103.0
PrimaryPK: Time to Reach Cmax (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Median · hour
PK: Time to Reach Cmax (Tmax) of Selpercatinib
hour320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Time to Reach Cmax (Tmax) of Selpercatinib1.557 (0.80 to 24.06)2.051 (0.82 to 4.09)
PrimaryPK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib

PK: Kel of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Mean · 1/hour
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib
1/hour320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib0.02515 ± 0.00879870.02459 ± 0.0070524
PrimaryPK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib

PK: t½ of Selpercatinib is reported.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.5, 2, 2.5, 3, 4, 7, 9, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Mean · hour
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib
hour320 mg Selpercatinib (Treatment A)640 mg Selpercatnib (Treatment B)
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib31.189 ± 11.698830.582 ± 9.2791

Adverse events

Collected over Baseline up to 41 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
320 mg Selpercatinib0/32 (0%)0/32 (0%)6/32 (18.8%)
640 mg Selpercatinib0/32 (0%)0/32 (0%)2/32 (6.3%)
400 mg Moxifloxacin0/32 (0%)0/32 (0%)0/32 (0%)
Selpercatinib Matching Placebo0/32 (0%)0/32 (0%)4/32 (12.5%)
Most frequent other events
Most frequent other events
Event320 mg Selpercatinib640 mg Selpercatinib400 mg MoxifloxacinSelpercatinib Matching Placebo
ConstipationGastrointestinal disorders2/320/320/324/32
NauseaGastrointestinal disorders2/320/320/320/32
Vessel puncture site painGeneral disorders0/322/320/320/32
Nasal congestionRespiratory, thoracic and mediastinal disorders2/320/320/320/32

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBATotal
Mean35.0 ± 11.4440.3 ± 8.7844.0 ± 8.8810.18 ± 10.1840.5 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBATotal
Female786526
Male10236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBATotal
Hispanic or Latino244414
Not Hispanic or Latino644418
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBATotal
American Indian or Alaska Native01001
Asian00000
Native Hawaiian or Other Pacific Islander10001
Black or African American11204
White566825
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: BDACTreatment Sequence 3: CADBTreatment Sequence 4: DCBATotal
United States888832
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2019, 2 months.

Results were first posted in Sep 2025, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Nov 29, 2022
StartActual
Apr 16, 2019
Primary completionActual
Jun 21, 2019
CompletionActual
Jun 21, 2019
Results first posted
Sep 18, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05630274
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Apr 16, 2019
Primary completion
Jun 21, 2019
Completion
Jun 21, 2019
Results posted
Sep 18, 2025
Last update
Sep 18, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion